Beamion LUNG-1 (NCT04886804): trial design/endpoints1
aRandomized to receive either 240 mg or 120 mg QD. One dose will be selected after interim analysis bExcluding patients pretreated with ADCs
1. Wu Y, et al. ELCC 2024. Poster 34P; 2. NCT04886804. https://clinicaltrials.gov/ct2/show/study/NCT04886804. Accessed April 2024.